Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Interest & Investment Income of $1.5 million for Q2 2026, down 15.5% year-over-year from $1.8 million in Q2 2025, and down 13.02% quarter-over-quarter from $1.7 million in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Interest & Investment Income for 8 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 15.5% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $5.9 million (down 49.67% YoY), while the FY2025 annual figure was $7.0 million, down 53.53% from the prior year.
- Interest & Investment Income retreated to $1.5 million in Q2 2026 per PHAT's latest filing, from $1.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.3 million in Q1 2024 and bottomed at $7000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.0 million across 5 years, with a median of $1.6 million in 2026.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 21350.0% — and 2025, when it sank 65.7%.
- Phathom Pharmaceuticals' Interest & Investment Income stood at $1.3 million in 2022, then surged by 160.14% to $3.3 million in 2023, then climbed by 4.84% to $3.5 million in 2024, then tumbled by 65.7% to $1.2 million in 2025, then climbed by 25.42% to $1.5 million in 2026.
- Business Quant data shows PHAT's Interest & Investment Income at $1.5 million in Q2 2026, $1.7 million in Q1 2026, and $1.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | 1.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.51 Mn |
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 2.72 Mn |
| Jun 30, 2023 | 348,000.00 |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.29 Mn |
| Sep 30, 2022 | 726,000.00 |
| Jun 30, 2022 | 112,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 8,000.00 |